# A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

> **NCT05703984** · PHASE1 · UNKNOWN · sponsor: **GC Biopharma Corp** · enrollment: 50 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** GC2129A(Period 1)
- **DRUG:** Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
- **DRUG:** GC2129A(Period 2)
- **DRUG:** Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)

## Key facts

- **NCT ID:** NCT05703984
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-17
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703984, "A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05703984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*